Bodyport

Bodyport is a medical device and software company that provides remote monitoring solutions for heart failure patients. The company's core offering combines the FDA-cleared Bodyport Cardiac Scale with proprietary algorithms to non-invasively measure hemodynamic biomarkers through a patient's feet in under 30 seconds.

The platform's Congestion Index aggregates multiple hemodynamic measurements into a single composite metric designed to detect early signs of worsening heart failure. The solution includes a clinical portal for care teams, a patient mobile app, RPM billing support, and API integration capabilities for EHR connectivity. The system is HIPAA-compliant and SOC 2-certified.

Bodyport has published clinical validation studies in peer-reviewed medical journals including the Journal of Cardiac Failure. In the SCALE-HF 1 study, the Congestion Index detected 70% of heart failure events—twice the rate of traditional weight-based monitoring—while generating 88% fewer false alerts. The company partners with major health systems and pharmaceutical companies for research and implementation.

Consider Bodyport when your organization needs to move beyond traditional weight-based heart failure monitoring and requires clinical evidence of improved detection rates. The platform is particularly well-suited for health systems conducting cardiovascular research or implementing value-based care models where reducing heart failure readmissions is a priority.

Expect a managed service model with hardware provisioning, cellular connectivity handled by the vendor, and a care platform that integrates with existing clinical workflows. The solution provides actionable alerts designed to support earlier clinical intervention while reducing false positives.

Bodyport operates exclusively in healthcare with specific focus on cardiovascular disease management and heart failure monitoring. The company has designed its platform around the clinical workflows of cardiology practices and heart failure clinics, with features including RPM billing code support (CPT codes for remote physiologic monitoring), HIPAA-compliant data handling, and integration capabilities with major EHR systems.

The company collaborates with pharmaceutical partners like Boehringer Ingelheim and conducts clinical research with academic medical centers specifically studying heart failure populations. All product development is centered on cardiovascular clinical validation and peer-reviewed publication in cardiology journals.

Mid-to-large health systems with dedicated heart failure management programs, cardiology practices with 100+ heart failure patients, and accountable care organizations focused on reducing readmissions. Organizations with existing RPM infrastructure seeking to improve clinical outcomes, research-oriented institutions interested in cardiovascular monitoring innovation, and value-based care providers managing high-risk heart failure populations.